Resources

Resources

These resources are provided to help health care professionals suspect and detect ATTR-CM more promptly and precisely in their patients.

Suspect Resources Detect Resources

Suspect Resources

Revealing ATTR-CM in Clinical Practice: Seeing the Signs

Presented by:

Dr. Pablo Garcia-Pavia

Heart Failure and Inherited Cardiac Diseases Units
Hospital Universitario Puerta de Hierro
Madrid, Spain

Join Dr. Garcia-Pavia as he presents an overview of ATTR-CM and highlights the clinical clues that raise suspicion of the disease. Dr. Garcia-Pavia also introduces the case of a patient with suspected ATTR-CM.

DETECT RESOURCES

Revealing ATTR-CM in Clinical Practice: Confirming the Diagnosis

Presented by:

Dr. Pablo Garcia-Pavia

Heart Failure and Inherited Cardiac Diseases Units
Hospital Universitario Puerta de Hierro
Madrid, Spain

In this video, Dr. Garcia-Pavia reviews selected noninvasive and invasive approaches for diagnosing ATTR-CM to help clinicians put the clues together and unmask ATTR-CM in practice. Dr. Garcia-Pavia also presents a case of a patient who is diagnosed with ATTR-CM.

A Summary of
Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis

The standardization of echocardiography, cardiac magnetic resonance, and radionuclide imaging in the evaluation of ATTR-CM is an unmet need that could potentially increase diagnoses and improve quality of care and patient outcomes.

Nuclear scintigraphy is a noninvasive, readily available diagnostic tool with high sensitivity and specificity for ATTR-CM when combined with testing to rule out AL amyloidosis.1,2

This summary is adapted from ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Evidence Base and Standardized Methods of Imaging and Diagnostic Criteria and Appropriate Utilization, Parts 1 and 2.
The original piece was prepared independently by a multisocietal expert consensus panel, and Pfizer is not responsible for its content.

Document format: PDF
MECR-Resources

FREE GENETIC TESTING AND COUNSELING

In order to empower individuals facing ATTR-CM and their health care providers, Pfizer and its partners, Centogene and GeneMatters, are offering anonymous genetic testing and counseling, at no cost, to eligible individuals with ATTR-CM or at risk of developing it.ATTR-Informed

Go to ATTRINFORMED.com to learn more about this free genetic testing and counseling program

GET SUSPECT AND DETECT ATTR-CM UPDATES

Sign up to be alerted about new educational resources
to help you suspect and detect ATTR-CM.

Sign Up